Quick Answer
AXIM BIOTECHNOLOGIES, INC. reported Research And Development Expense of $125.5 thousand for the year ending 2023.
- AXIM BIOTECHNOLOGIES, INC. showed a decrease of -18.3% in Research And Development Expense from 2022 to 2023.
- This data is from AXIM BIOTECHNOLOGIES, INC.'s annual report (Form 10-K), filed with the SEC on April 16, 2024.
- XBRL data for this metric is available from 2016 to 2023 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2014: $0.00 | Q3 2015: $133.1 thousand | Q1 2016: $31.2 thousand | Q2 2016: $45.0 thousand | Q3 2016: $87.7 thousand | Q1 2017: $140.4 thousand | Q2 2017: $62.9 thousand | Q3 2017: $632.7 thousand | Q1 2018: $678.7 thousand | Q2 2018: $672.7 thousand | Q3 2018: $350.6 thousand | Q1 2019: $532.7 thousand | Q2 2019: $991.6 thousand | Q3 2019: $426.7 thousand | Q2 2020: $121.4 thousand | Q3 2020: $109.1 thousand | Q1 2021: $101.0 thousand | Q2 2021: $48.1 thousand | Q3 2021: $67.3 thousand | Q1 2022: $44.2 thousand | Q2 2022: $35.2 thousand | Q3 2022: $29.7 thousand | Q1 2023: $20.3 thousand | Q2 2023: $34.1 thousand | Q3 2023: $34.7 thousand | Q1 2024: $15.5 thousand | Q2 2024: $4.1 thousand.
- Over the full 6 years of available data (2016 to 2023), AXIM BIOTECHNOLOGIES, INC.'s Research And Development Expense has declined by 46.7%.
- Historical annual values: Fiscal year 2023: $125.5 thousand | Fiscal year 2022: $153.7 thousand | Fiscal year 2021: $284.9 thousand | Fiscal year 2018: $2.06 million | Fiscal year 2017: $1.35 million | Fiscal year 2016: $235.6 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: